ArticleOncology letters2026
Curcumin induces and enhances the PARP1-mediated parthanatos in diffuse large B cell lymphoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults. Although the development and application of novel therapeutic agents have improved patient survival, primary drug resistance and the management of relapsed/refractory disease remain major challenges. Curcumin, a natural polyphenol, exhibits broad-spectrum antitumor activity. However, its anti-DLBCL efficacy and underlying mechanisms have not been well characterized. The present study investigated whether curcumin inhibited DLBCL by inducing parthanatos, a form of programmed cell death. Results showed that curcumin exerted a concentration-dependent, caspase-independent cytotoxic effect on DLBCL cells, accompanied by an increase in DAPI-positive/propidium iodide-positive cells. Western blotting analysis revealed that curcumin upregulated poly(ADP-ribose) and poly(ADP-ribose) polymerase 1 (PARP-1) expression in whole-cell lysates. Moreover, nuclear expression levels of apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor were significantly elevated compared with their cytoplasmic levels. Immunofluorescence staining further confirmed the increased nuclear localization of PARP-1 and AIF. Furthermore, low-dose curcumin combined with ultraviolet B (UVB) irradiation synergistically induced parthanatos in DLBCL cells. Notably, olaparib, a specific PARP-1 inhibitor, attenuated activation of parthanatos induced by curcumin alone or in combination with UVB. In summary, the present findings suggest that curcumin inhibits DLBCL cell proliferation through PARP1-mediated parthanatos and exhibits synergistic effects with UVB irradiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.